CNS Pharmaceuticals Inc. Common Stock (CNSP)
Stock · NASDAQ · Health Care
$4.85as of 10/16/2026
Price chart
Active signals
CNSP Signal Track Record
How signals performed across all stocks →What CNSP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band BreakdownActive now | 24 | -16.3% | 38% | September 17, 2026 |
| Bollinger Band Breakout | 19 | -27.3% | 16% | July 8, 2026 |
| Volume Spike | 19 | -19.0% | 26% | May 4, 2026 |
| 200-Day Moving Average TouchActive now | 5 | +7.9% | 60% | August 12, 2026 |
| Any 20-session window (baseline) | -11.5% | 30% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblasto…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 8
- Website
- cnspharma.com/
Fundamentals
- 1-day range
- $4.65$5
- Market cap
- $7.65M
- P/E (trailing)
- —
- P/E (forward)
- -11.92
- EPS (trailing)
- $-23.14
- Dividend yield
- —
- Beta
- 1.06
- Avg. volume
- 6.3K
Forecasts
1 analyst ratings
CNS Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CNSPCNS Pharmaceuticals Inc. Common Stock$4.85▼ 6.30%Market cap $7.65MP/E —$1.9$10.54
- PCSAProcessa Pharmaceuticals Inc. Common Stock$1.69▲ 0.60%Market cap $7.65MP/E 3.31$1.04$11
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$1.76▼ 4.86%Market cap $7.63MP/E —$299$9,000,000
- MBRXMoleculin Biotech Inc. Common Stock$0.28▼ 24.32%Market cap $7.50MP/E —$0.1614$15.75
- MTVAMetaVia Inc. Common Stock$1.26▼ 8.03%Market cap $7.49MP/E —$0.9661$14.85
- APREAprea Therapeutics Inc. Common stock$0.584▼ 5.50%Market cap $7.83MP/E —$0.548$1.69
- BOLTBolt Biotherapeutics Inc. Common Stock$4▼ 5.66%Market cap $7.44MP/E —$3.1$7.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CNSP CNS Pharmaceuticals Inc. Common Stock | $7.65M | — | $4.85 | ▼ 6.30% | $1.9$10.54 |
| PCSA Processa Pharmaceuticals Inc. Common Stock | $7.65M | 3.31 | $1.69 | ▲ 0.60% | $1.04$11 |
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $7.63M | — | $1.76 | ▼ 4.86% | $299$9,000,000 |
| MBRX Moleculin Biotech Inc. Common Stock | $7.50M | — | $0.28 | ▼ 24.32% | $0.1614$15.75 |
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.26 | ▼ 8.03% | $0.9661$14.85 |
| APRE Aprea Therapeutics Inc. Common stock | $7.83M | — | $0.584 | ▼ 5.50% | $0.548$1.69 |
| BOLT Bolt Biotherapeutics Inc. Common Stock | $7.44M | — | $4 | ▼ 5.66% | $3.1$7.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks TranscriptSeekingAlpha · 9/30/2026
Insider Activity
Insider Actions →- Levin Rami · August 14, 2026 · Option Exercise4.8K
- Fisher Michal · May 18, 2026 · Buy2.0K @ $5
- Faith L. Charles · May 18, 2026 · Buy7.1K @ $4.79
Institutional Ownership
March 31, 2026
- Total shares held
- 145.6K
- Total value held
- $348.7K
- Institutional holders
- 11
- Unknown61.0K
- Unknown45.8K
- Unknown23.2K
- Unknown13.5K
- Unknown1.3K
- Unknown729
- Unknown8
- Unknown3
- Unknown1
- Unknown1
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CNS Pharmaceuticals Holds Shareholder/Analyst Call
On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.
CNS Pharmaceuticals Holds Shareholder/Analyst Call. On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.